MUMBAI, India, July 11 -- Intellectual Property India has published a patent application (202541060216 A) filed by Saveetha Institute Of Medical And Technical Sciences, Chennai, Tamil Nadu, on June 24, for 'development of hyaluronic acid modified nanoemulsions for cd44 targeted delivery of natural flavonoi.'
Inventor(s) include Dr. Selvaraj Jayaraman; Dr. Vishnu Priya Veeraraghavan; and Dr. Deepak Nallaswamy Veeraiyan.
The application for the patent was published on July 11, under issue no. 28/2025.
According to the abstract released by the Intellectual Property India: "Gastric cancer is one of the leading causes of cancer-related mortality, and current treatment strategies, including chemotherapy, face limitations such as systemic toxicity, lack of specificity, and multidrug resistance. These challenges underscore the need for innovative drug delivery systems capable of selectively targeting tumor cells while minimizing damage to healthy tissues. One promising approach is the use of biofunctionalized .nanoemulsions that can deliver natural therapeutic compounds directly to cancer cells. This study aims to develop and evaluate a novel hyaluronic acid (HA)-modified nanoemulsion platform designed to deliver hydrophobic natural flavonoids to CD44-positive gastric cancer cells. By exploiting the CD44 receptor, which is overexpressed on many gastric cancer cells, the study investigates how this targeted delivery system can enhance the solubility, stability, and therapeutic efficacy offlavonoids while improving the specificity and efficacy of cancer treatment.HA-modified nanoemulsions were engineered by conjugating hyaluronic acid to the surface of lipid-based nanoemulsions. These nanoemulsions were encapsulated with natural flavonoids known for their anticancer, antioxidant, and antiinflammatory properties. The in vitro effectiveness of the nanoemulsions was assessed using gastric cancer cell lines, such as AGS and MKN-45, to evaluate cellular uptake, cytotoxicity, and targeted delivery. The HA-modified nanoemulsions significantly enhanced the cellular uptake of flavonoids by CD44-positive gastric cancer cells. These formulations showed improved solubility and stability of the encapsulated flavonoids, leading to increased therapeutic efficacy. The nanoemulsions demonstrated selective cytotoxicity against gastric cancer cells, with minimal toxicity to normal cells. The hyaluronic acid-modified nanoemulsions provide an effective and targeted drug delivery system for the treatment of gastric cancer. This innovative platform enhances the therapeutic potential of natural flavonoids and offers a promising approach for targeted cancer therapies, with potential applications in other CD44-overexpressing malignancies."
Disclaimer: Curated by HT Syndication.
